News & Updates

Treatment with bimekizumab for up to 2 years appears to be tolerated well in patients with moderate-to-severe plaque psoriasis, with no increased risk of adverse events (AEs) aside from a higher frequency of mild-to-moderate oral candidiasis, according to pooled analyses of data from eight randomized controlled trials (RCTs).

Extended duration perioperative thromboprophylaxis with low molecular weight heparin tinzaparin (administered before and for 56 days after surgery) does not lead to longer disease-free survival at 3 years in patients with localized invasive colorectal cancer undergoing surgical resection, reports a study.

In the phase II TRAIL1 trial, oral pirfenidone slowed the rate of decline in lung function in individuals with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.